Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 13;15(3):e096438.
doi: 10.1136/bmjopen-2024-096438.

Barriers to annual diabetic retinopathy screening and subsequent recommended follow-up adherence among Chinese diabetics: a cross-sectional and longitudinal study

Affiliations

Barriers to annual diabetic retinopathy screening and subsequent recommended follow-up adherence among Chinese diabetics: a cross-sectional and longitudinal study

Tiezhu Lin et al. BMJ Open. .

Abstract

Objectives: Adherence to routine annual eye evaluations for diabetes is frequently insufficient on a global scale. We evaluated the adherence to annual diabetic retinopathy screening (DRS) and recommended follow-up among Chinese patients with diabetes, and we also identified the associated risk variables.

Design: This was a cross-sectional and longitudinal study.

Setting: Patients with diabetes were inquired about their completion of DRS within the preceding year. All participants were required to complete the Compliance with Annual Diabetic Eye Exams Survey.

Participants: Participants with diabetes who initially sought eye examination from November 2021 to October 2023 at He Eye Specialist Hospital, Shenyang, China.

Outcome measures: Logistic regression analyses defined the risk factors associated with poor compliance with the annual DRS and recommended follow-up.

Results: There were 468 patients registered, with a mean age of 67.42±10.66 years. A total of 308 (65.8%) participants had DRS in the previous year. Rural residents (OR 1.704, 95% CI 1.019 to 2.850, p=0.042), vision-threatening diabetic retinopathy (VTDR) (OR 1.948, 95% CI 1.145 to 3.313, p=0.014), item 7 (over the past 4 weeks, I have felt blue, downhearted or depressed) (OR 0.624, 95% CI 0.401 to 0.971, p=0.037) and item 42 (I receive a reminder from my eye doctor's office when it is time to schedule an exam) (OR 0.618, 95% CI 0.387 to 0.989, p=0.045) were associated with non-adherence to annual DRS. The compliance with DRS improved to 80.9% in the second year after health education and reminders of follow-up. VTDR (OR 3.063, 95% CI 1.852 to 5.066, p<0.01) was found to be the risk factor for poor compliance with scheduled follow-up.

Conclusions: About one-third of diabetics did not complete annual DRS; that rate decreased to one-fifth after health education and follow-up reminders.

Keywords: Diabetes Mellitus, Type 2; Diabetic retinopathy; Risk Factors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. Diagram illustrating the inclusion and exclusion of study participants. CADEES, Compliance with Annual Diabetic Eye Exams Survey; DM, diabetes mellitus; DR, diabetes retinopathy; OCT, optical coherence tomography; SLO, scanning laser ophthalmoscope.

References

    1. Teo ZL, Tham Y-C, Yu M, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology. 2021;128:1580–91. doi: 10.1016/j.ophtha.2021.04.027. - DOI - PubMed
    1. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group Early Photocoagulation for Diabetic Retinopathy. Ophthalmology. 1991;98:766–85. doi: 10.1016/S0161-6420(13)38011-7. - DOI - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806. doi: 10.1001/archopht.1985.01050120030015. - DOI - PubMed
    1. Gross JG, Glassman AR, Liu D, et al. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136:1138–48. doi: 10.1001/jamaophthalmol.2019.0032. - DOI - PMC - PubMed
    1. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127:66–145. doi: 10.1016/j.ophtha.2019.09.025. - DOI - PubMed

Supplementary concepts

LinkOut - more resources